EPC 003
Alternative Names: EPC-003Latest Information Update: 03 Aug 2026
At a glance
- Originator Elpis Biopharmaceuticals
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Glioblastoma
Most Recent Events
- 02 Jun 2026 Pharmacodynamics and adverse event data from preclinical studies in Glioblastoma presented at the 62nd Annual Meeting of the American Society of Clinical Oncology 2026 (ASC0-2026)
- 29 May 2026 Efficacy and adverse evenet data from a phase I trial in Glioblastoma presented at the 62nd Annual Meeting of the American Society of Clinical Oncology 2026 (ASCO-2026)
- 26 Sep 2025 Phase-I clinical trials in Glioblastoma (Second-line therapy or greater, Recurrent) in China (Intraventricular) (NCT07193628)